retatrutide efficacy weight loss 🚨 TRIUMPH-1: #retatrutide topline data🚨 Phase 3, n=2,339, 80 wk, obesity without diabetes (efficacy estimand): 🔹 12 mg: -28.3% body (-31.9 kg) 🔸 9 mg: -25.9% Pack Type:Stick Packs (3 month/90 servings) Men's Health Difference Between GLP-1 and

retatrutide efficacy weight loss 🚨 TRIUMPH-1: #retatrutide topline data🚨 Phase 3, n=2,339, 80 wk, obesity without diabetes (efficacy estimand): 🔹 12 mg: -28.3% body (-31.9 kg) 🔸 9 mg: -25.9% Pack Type:Stick Packs (3 month/90 servings) Men's Health Difference Between GLP-1 and

Difference Between GLP-1 and Semaglutide: 5 IMP Facts Explained

Patients should start gradually and increase activity as tolerated, avoiding overexertion

Men's Health

Pack Type:Stick Packs (3 month/90 servings)

Predicted coverage changes post-approval: Based on the coverage expansion pattern when Wegovy gained FDA approval for obesity in 2021, we expect: 60-70% of large-employer commercial plans to cover GLP-1s for NASH within 6 months of FDA approval 30-40% of marketplace plans to add coverage within 12 months Medicare Part D to cover for NASH (but not for obesity, due to the statutory weight-loss drug exclusion) Medicaid coverage to remain state-specific, with 15-20 states adding NASH coverage within 18 months Prior authorization will still be required, but approval rates will flip from 25% (current off-label rate) to 70-80% (typical for newly approved indications)